Synopsis: Healthcare stock surged 12 percent after FY26 results, driven by strong biotech growth, emerging market expansion, margin improvement, and a turnaround in profitability to Rs 199 crore PAT.
The share of this company, which focuses on pharmaceutical formulations, biotechnology (insulin and erythropoietin), and hospital services (Wockhardt Hospitals), gained investor traction after strong Q4 numbers
With a market capitalization of Rs 25,194 crore, Wockhardt Ltd’s share on Tuesday made a day high of Rs 1.602.20 per share, up by 12.3 percent from its previous close price of Rs 1,425.50 per share. The shares of this company have given a return of 194 percent over the last five years, and it’s backed by ace investor Rekha Jhunjhunwala, who holds about 1.75 percent stake.
Results Overview
QoQ View: Revenue from operations increased from Rs 888 crore in Q3 FY26 to Rs 965 crore in Q4 FY26, marking a QoQ rise of about 8.7 percent, indicating steady top-line growth. EBITDA improved from Rs 173 crore to Rs 196 crore, up around 13.3 percent QoQ, showing better operating efficiency.
Profit after tax rose sharply from Rs 61 crore to Rs 164 crore, a strong jump of nearly 169 percent QoQ, driven by improved operating performance and likely lower costs or higher margins.
YoY View: Revenue from operations rose from Rs 743 crore in Q4 FY25 to Rs 965 crore in Q4 FY26, marking a YoY growth of about 29.9 percent, indicating strong expansion in the business. EBITDA improved sharply from Rs 79 crore to Rs 196 crore, a rise of nearly 148 percent YoY, reflecting significant improvement in operating performance and margins.
Profit after tax showed a strong turnaround from a loss of Rs 45 crore in Q4 FY25 to a profit of Rs 164 crore in Q4 FY26, highlighting a major improvement in profitability driven by higher revenues and better cost control.
Fiscal Year comparison: Revenue from operations increased from Rs 3,033 crore in FY25 to Rs 3373 crore in FY26, marking a YoY growth of about 11.2 percent, indicating steady business expansion.
EBITDA improved from Rs 480 crore to Rs 630 crore, a rise of nearly 31.3 percent YoY, supported by better operating leverage. EBITDA margin also expanded sharply from 13.8 percent in FY25 to 18.7 percent in FY26, reflecting improved cost efficiency and stronger pricing or mix benefits.
Profit after tax showed a strong turnaround from a loss of Rs 57 crore in FY25 to a profit of Rs 199 crore in FY26, with PAT margin at 5.6 percent, highlighting a meaningful shift from losses to sustained profitability.
Q4 Business Highlights
- India Branded Business: India Branded Business stood at Rs 112 crore in Q4 FY26, up 18 percent YoY, and Rs 523 crore in FY26, up 15 percent YoY. Growth was driven by strong performance in diabetic therapy, NCE (EMROK), and expansion in regenerative derma segment, reflecting steady domestic demand and portfolio strength.
- UK Region: UK revenue came in at Rs 349 crore in Q4 FY26, growing 20 percent YoY, while FY26 revenue stood at Rs 1318 crore, up 13 percent YoY. Growth was supported by stable product demand and consistent market penetration, indicating resilient performance in the region.
- Emerging Markets & Ireland: Emerging Markets recorded Rs 320 crore in Q4 FY26, surging 124 percent YoY, and Rs 958 crore in FY26, up 35 percent YoY, led by Biotech Insulin and Latam traction. Irish region posted Rs 52 crore in Q4 FY26, up 12 percent YoY, and Rs 209 crore in FY26, growing 16 percent YoY, showing steady incremental growth.
- Biotech Quarterly Performance: Biotech operations stood at Rs 252 crore in Q4 FY26, rising 126 percent YoY, driven by strong growth across biosimilars and insulin-related products. The performance reflects robust demand in key markets and expanding business scale across geographies.
- Full Year Growth and Outlook: On a full-year basis, biotech revenue reached Rs 697 crore in FY26, up 27 percent YoY, supported by Emerging Markets growth of over 34 percent and new partnerships across Thailand, Egypt, Algeria, and LATAM. India Biotech continued double-digit growth, while upcoming insulin analog launches are expected to further strengthen long-term prospects in diabetes care.
What led the turnaround in financial performance
- Strong biotech-led growth: Biotech revenue rose 126 percent YoY in Q4 FY26 to Rs 252 crore and 27 percent to Rs 697 crore in FY26, driven by higher scale in biosimilars and insulin products, supporting earnings recovery.
- Emerging markets momentum: Emerging markets grew 124 percent YoY in Q4 and 35 percent in FY26, led by insulin traction and expansion in Thailand, Egypt, Algeria, and LATAM, boosting overall profitability.
- Stable core market performance: India branded business grew 15 percent and UK business 13 percent in FY26, providing steady base revenue alongside high-growth segments.
- Strong pipeline visibility: Five antibiotics cleared Phase 3, with assets like Zaynich and Miqnaf advancing toward approvals, improving long-term earnings outlook.
About the Company
Wockhardt India is a research-based, global pharmaceutical and biotechnology conglomerate headquartered in Mumbai. Founded in 1967, it operates in pharmaceuticals, biopharmaceuticals, and hospitals, focusing on complex generics and antibiotic research. Its major offerings include diabetes care (Wosulin, Glaritus), nephrology (Wepox), pain management (Methycobal, Spasmo Proxyvon), and critical care antibiotics.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
